Abstract: The present invention relates to a pharmaceutical composition comprising an anti-cancer drug and an inhibitor of bone morphogenetic protein 4 (BMP-4) or its gene expression. The present invention also relates to methods of treating cancer and prognostic methods.

Abstract: In overview, the technology is primarily directed to the implementation of linked gaming in respect of a plurality of gaming machines. In particular, a controller device is disclosed, this controller device being adapted to enable the management of a plurality of linked games via a single piece of hardware. This is achieved in part by virtualization of jackpot controllers within the controller device. More specifically, a user is enabled to configure a plurality of virtual jackpot controllers by way of interaction with a graphical user interface, and select compatible electronic gaming machines to participate in a linked game provided by a given one of the virtual jackpot controllers.

Abstract: Fluorescent screens and display systems and devices based on such screens using at least one excitation optical beam to excite one or more fluorescent materials on a screen which emit light to form images. The fluorescent materials may include phosphor materials and non-phosphor materials such as quantum dots. A screen may include a multi-layer dichroic layer.

Abstract: The present invention in one aspect relates to a method for treating cancer or enhancing a cancer treatment, the method comprising inhibiting the expression of an oligonucleotide encoding for a protein selected from the group consisting of OLFM4, SP5, TOB1, ARID1A, FBN1 and HAT1, by administering to a mammal in need of cancer treatment an effective amount of at least one silencing oligonucleotide comprising a binding motif for binding to the oligonucleotide encoding for a protein.

Abstract: The invention provides an in vitro method for predicting clinical outcome of a patient affected with a non-small cell lung carcinoma (NSCLC), which method comprises determining the expression level of at least 8 genes in a biological sample of said patient.

Abstract: The invention relates to methods for diagnosis and prognosis of gastric cancer. The approach described herein can distinguish intestinal-type gastric cancer (G-INT) from diffuse-type gastric cancer (G-DIF). The genomic expression signatures of G-INT and G-DIF define two major sets of genes. A diagnosis of gastric cancer G-INT and G-DIF can be made on the basis of the expression levels of these genes. This can lead to a better prognosis and treatment of gastric cancer.

Abstract: A method of treating or preventing a gastrointestinal cancer by inhibiting expression of a CD44-SLC1A2 fusion gene or a functional variant thereof, or by inhibiting the activity of a fusion protein expressed by the CD44-SLC1A2 fusion gene or the functional variant thereof.

Abstract: One embodiment described herein is directed to a method practiced in a computing environment. The method includes acts for determining test suite effectiveness for testing for concurrency problems and/or product faults. The method includes identifying a plurality of synchronization primitives in a section of implementation source code. One or more of the synchronization primitives are iteratively modified and a same test suite is run for each iteration. For each iteration, a determination is made whether or not the test suite returns an error as a result of modifying one or more synchronization primitives. When the test suite does not return an error, the method includes providing to a user an indication which indicates at least one of a test adequacy hole for the test suite; an implementation source code fault; or an equivalent mutant of the implementation source code.

Abstract: The invention provides an in vitro method for predicting clinical outcome of a patient affected with a non-small cell lung carcinoma (NSCLC), which method comprises determining the expression level of at least 8 genes in a biological sample of said patient.

Abstract: One embodiment described herein is directed to a method practiced in a computing environment. The method includes acts for determining test suite effectiveness for testing for concurrency problems and/or product faults. The method includes identifying a plurality of synchronization primitives in a section of implementation source code. One or more of the synchronization primitives are iteratively modified and a same test suite is run for each iteration. For each iteration, a determination is made whether or not the test suite returns an error as a result of modifying one or more synchronization primitives. When the test suite does not return an error, the method includes providing to a user an indication which indicates at least one of a test adequacy hole for the test suite; an implementation source code fault; or an equivalent mutant of the implementation source code.

Abstract: Fluorescent screens and display systems and devices based on such screens using at least one excitation optical beam to excite one or more fluorescent materials on a screen which emit light to form images. The fluorescent materials may include phosphor materials and non-phosphor materials such as quantum dots. A screen may include a multi-layer dichroic layer.

Abstract: Fluorescent screens and display systems and devices based on such screens using at least one excitation optical beam to excite one or more fluorescent materials on a screen which emit light to form images. The fluorescent materials may include phosphor materials and non-phosphor materials such as quantum dots. A screen may include a multi-layer dichroic layer.

Abstract: A device includes a scan circuit including a scan chain. The scan chain includes a first plurality of scan cells that receive a first scan clock signal in a first clock domain. A second plurality of scan cells receives a second scan clock signal in a second clock domain. A scan clock source generates the first scan clock signal and the second scan clock signal, and selectively inverts the first scan clock signal and the second scan clock signal based on an operating mode of the first plurality of scan cells and the second plurality of scan cells, respective flip-flop arrangements of the first clock domain and the second clock domain.

Abstract: Fluorescent screens and display systems and devices based on such screens using at least one excitation optical beam to excite one or more fluorescent materials on a screen which emit light to form images. The fluorescent materials may include phosphor materials and non-phosphor materials such as quantum dots. A screen may include a multi-layer dichroic layer.

Abstract: In one embodiment, an apparatus comprises a scan circuit including at least a first and a second clock domain and a scan chain having a first plurality of scan cells positioned in the first clock domain and a second plurality of scan cells positioned in the second clock domain. A scan clock source, coupled to the scan chain, generates a first scan clock signal to the first plurality of scan cells and a second scan clock signal to the second plurality of scan cells. The first and the second clock signals have an inverted relationship.

Abstract: The invention provides materials and methods for classifying breast cancer in patients. Particularly there is provided a novel gene expression signature which acts as a predictive signature for response to treatment including hormonal therapies (e.g. tamoxifen) and chemotherapy.

Abstract: Classification of breast tumours into Estrogen Receptor positive and negative (ER+ and ER?) subtypes is an important distinction in the treatment of breast cancer. ER typing is frequently performed using expression profiles of genes whose expression is known to be affected by ER activity. Some tumours cannot confidently be assigned to a particular ER type based on such expression data. The present inventors have found that such “low confidence” tumours constitute a distinct biological subtype of breast tumours associated with significantly worse overall survival than high confidence tumours. Gene sets capable of distinguishing low confidence from high confidence tumours are provided, along with methods and apparatus for performing appropriate classification of breast tumours.

Abstract: A new method to prevent cracking at the corners of a semiconductor die during dicing is described. Dummy metal structures are fabricated at the corners of the die to prevent cracking. The design for the dummy metal structures can be generated automatically by a computer program.

Abstract: The inventors set out to identify a set of genes for use as prognostic markers for breast tumours which correlate with the Nottingham Prognostic Index (NPI). Initially they were unable to identify a single set of genes whose expression correlates with the NPI. However after segregating the dataset into molecular subcategories (estrogen receptor positive, estrogen receptor negative, and ErbB2 positive) they identified a set of 62 genes which are differentially expressed in tumours of different prognoses. Methods and apparatus for determining prognosis are provided. Also provided are methods of determining the response of tumours to chemotherapy involving comparing the expression levels of the predictive gene set before and after treatment.